Dr. Robert F Weiss, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 800 Post Rd, Darien, CT 06820 Phone: 203-656-1696 Fax: 203-656-1742 |
Josephine Velazquez, D.P.M. Podiatrist - Sports Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Old Kings Hwy S, Darien, CT 06820 Phone: 203-655-6299 Fax: 203-656-2607 |
The Foot & Ankle Institute Of Darien Llc Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 800 Post Rd, Darien, CT 06820 Phone: 203-656-1696 Fax: 203-656-1742 |
Dr. Scott H Weiss, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 Post Rd, Suite 302, Darien, CT 06820 Phone: 203-656-1696 Fax: 203-656-1742 |
Dr. Matthew Juriga, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 800 Post Rd, Suite 302, Darien, CT 06820 Phone: 203-656-1696 Fax: 203-656-1742 |
Dr. Rachel Hannah Albright, DPM Podiatrist - Foot & Ankle Surgery Medicare: Accepting Medicare Assignments Practice Location: 800 Post Rd Ste 302, Darien, CT 06820 Phone: 203-656-1696 Fax: 203-656-1742 |
News Archive
The benefits of continuous positive airway pressure machines (CPAP) for patients with obstructive sleep apnea (OSA) are quickly reversed when the therapy is withdrawn, according to Swiss research.
MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Prof. Kobi Rosenblum, Head of the Department of Neurobiology and Ethology at the University of Haifa, has been awarded a -1.6 million grant from DIP, a German-Israeli Project Cooperation, over a five-year period. This grant will fund Prof. Rosenblum's international research of the role of protein expression in memory formation and stability.
AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).
› Verified 8 days ago